• Propanc Biopharma highlighted new preclinical PRP data in pancreatic cancer models; results have already been presented.
• Studies showed strong tumor control, fewer metastases, and longer survival in animals, supporting a differentiated profile versus RAS-targeted therapy.
• PRP also appeared to remodel the tumor microenvironment and restore chemotherapy sensitivity, positioning it for combination or sequential use strategies.
• A multicenter, open-label Phase 1b first-in-human study is scheduled to start in Q1 2027, enrolling up to 50 advanced solid-tumor patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070830PRIMZONEFULLFEED9841236) on October 07, 2026, and is solely responsible for the information contained therein.